In the world of cancer research, no name stands above the crowd quite like that of Clay Siegall. After having spent more than 15 years as a senior researcher at some of the largest pharmaceutical firms in the entire world, Dr. Siegall was able to finally branch out on his own, founding Seattle Genetics. This company has proven to be one of the most successful new biotech startups in the history of the biopharmaceutical space, having gone from nothing to one of the most important manufacturers of targeted cancer therapy drugs in the world.
The stunning trajectory of Dr. Siegall’s singular career can be traced back to his days at the National Cancer Institute. There, Dr. Siegall first became familiarized with a new class of cancer-fighting drugs known as targeted cancer therapies. This exciting new area of cancer research grabbed Dr. Siegall’s attention. The new kind of drug promised to virtually eliminate all known side effects associated with chemotherapy, some of which were so severe that they actually limited the amount of drugs that can be safely administered to patients who needed them the most.
After spending four years at the National Cancer Institute, to stand out research your Dr. Clay Siegall was eventually recruited by one of the largest pharmaceutical companies in the world. He eventually accepted the position at Bristol-Myers Squibb, heading up a team of researchers that was looking into new ways to create targeted cancer therapies.
It was at Bristol-Myers Squibb that Dr. Siegall first had an epiphany. He realizes that human antibodies that were so effective at seeking out malignant issues could be weaponized, binding to them highly lethal cytotoxins that could be effectively carried directly to the site of the tumor. This new method of delivery would be able to completely eliminate all systemic release of chemotherapeutic drugs into the system of the subject to which they were being administered. This could effectively eliminate all side effects associated with chemotherapy, thereby dramatically increasing the safe dosage that can be administered to patients, even those in the late stages of cancer.